NCT05641935 Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
| NCT ID | NCT05641935 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | john eisenbrey |
| Condition | Recurrent Renal Cell Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 210 participants |
| Start Date | 2022-11-03 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 210 participants in total. It began in 2022-11-03 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.
Eligibility Criteria
Inclusion Criteria: * Previously received cryotherapy or microwave therapy of RCC * Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy * Have previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 4 weeks of the CEUS study * Be at least 18 years of age * Be medically stable * If a female of child-bearing age, must have a negative pregnancy test * Have signed Informed Consent to participate in the study Exclusion Criteria: * Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable * Patients with known sensitivities to the components of Lumason
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05641935 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Recurrent Renal Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05641935 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05641935 currently recruiting?
Yes, NCT05641935 is actively recruiting participants. Contact the research team at john.eisenbrey@jefferson.edu for enrollment information.
Where is the NCT05641935 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT05641935 clinical trial?
NCT05641935 is sponsored by john eisenbrey. The trial plans to enroll 210 participants.